Futura Medical Regulatory News (FUM)

Futura Medical plc

("Futura" or the "Company")

Result of General Meeting, Issue of Equity,

Admission and Total Voting Rights

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on transdermal technology, announces that, at its General Meeting held earlier today, all resolutions were duly passed.

Application will be made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM. Admission will take place in two tranches. It is expected that First Admission (consisting of 5,564,913 new Ordinary Shares) will be effective and trading will commence at 8.00 a.m. on 21 November 2016 and that Second Admission (consisting of 15,487,719 new Ordinary Shares) will be effective and trading will commence at 8.00 a.m. on 22 November 2016.

Immediately following Second Admission, the Company will have 120,144,950 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 120,144,950 and this figure may therefore be used by Shareholders from Second Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Terms in this announcement have the meaning given to them in the Circular issued in connection with the Placing and the announcement released on 27 October 2016 with the RNS Number 6448N.

For further information:

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange (AIM: FUM).

www.futuramedical.com